Published in J Renin Angiotensin Aldosterone Syst on August 08, 2011
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev (2000) 6.30
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens (2007) 1.86
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res (2010) 1.47
Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep (2008) 1.40
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem (2006) 1.38
Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem (1999) 1.19
Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol Pharmacol (1992) 1.09
Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst (2010) 1.08
"Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem (2004) 1.08
Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med Res Rev (2005) 1.07
Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem (2005) 1.07
Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol (2008) 1.05
A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects. Hypertens Res (2010) 1.03
Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes. Mol Pharmacol (1999) 0.97
Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol (1993) 0.94
Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci (2009) 0.90
Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists. J Renin Angiotensin Aldosterone Syst (2000) 0.82
Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A (2003) 3.99
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol (2003) 2.52
Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem (2002) 2.42
Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter. J Am Coll Cardiol (2004) 1.85
Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol (2002) 1.84
Reduction of P-wave duration and successful pulmonary vein isolation in patients with atrial fibrillation. J Cardiovasc Electrophysiol (2007) 1.82
Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev (2005) 1.73
Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler Thromb Vasc Biol (2009) 1.64
Addition of a Nitric Oxide Donor to an Angiotensin II Type 1 Receptor Blocker May Cancel Its Blood Pressure-Lowering Effects. Int Heart J (2015) 1.54
Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res (2012) 1.51
Association between hypertension and coronary artery disease as assessed by coronary computed tomography. J Clin Hypertens (Greenwich) (2011) 1.49
Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol (2012) 1.48
Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention--from the FU-registry. Circ J (2011) 1.45
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J (2010) 1.45
Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study. The STYLIST study. Circ J (2012) 1.44
Novel molecular imaging of atherosclerosis with gallium-68-labeled apolipoprotein A-I mimetic peptide and positron emission tomography. Circ J (2013) 1.43
Interaction of G-protein βγ complex with chromatin modulates GPCR-dependent gene regulation. PLoS One (2013) 1.43
Associations between metabolic factors and coronary plaque growth or arterial remodeling as assessed by intravascular ultrasound in patients with stable angina. Hypertens Res (2008) 1.42
Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep (2008) 1.40
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res (2004) 1.40
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem (2006) 1.38
Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis (2006) 1.33
Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest (2010) 1.26
Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res (2003) 1.15
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol (2007) 1.12
Domain coupling in GPCRs: the engine for induced conformational changes. Trends Pharmacol Sci (2011) 1.12
Coronary-pulmonary artery fistula with anomalous vessels arising from the right coronary sinus detected by 64-MDCT. Intern Med (2009) 1.11
Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem (2010) 1.10
High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol (2003) 1.09
Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst (2010) 1.08
"Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem (2004) 1.08
Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem (2005) 1.07
Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol (2007) 1.06
Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol (2003) 1.04
A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects. Hypertens Res (2010) 1.03
Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol (2010) 1.00
Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension (2003) 1.00
Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res (2010) 1.00
Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens Res (2004) 0.98
TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor. J Biol Chem (2002) 0.97
Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane Helix-2. J Biol Chem (2002) 0.95
Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol (2008) 0.93
Clinical significance of flow-mediated dilation, brachial intima-media thickness and pulse wave velocity in patients with and without coronary artery disease. Circ J (2012) 0.93
CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circ J (2003) 0.92
Association between coronary artery calcification score as assessed by multi-detector row computed tomography and upstroke time of pulse wave. Intern Med (2007) 0.92
Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis (2005) 0.91
Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation. J Vasc Res (2003) 0.91
Splicing variant of Cdc42 interacting protein-4 disrupts beta-catenin-mediated cell-cell adhesion: expression and function in renal cell carcinoma. Biochem Biophys Res Commun (2005) 0.90
Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med (2008) 0.90
Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J (2007) 0.90
Statins induce the regression of left ventricular mass in patients with angina. Circ J (2004) 0.90
Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 0.89
Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol (2003) 0.89
Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor. J Biol Chem (2012) 0.89
G-protein-dependent cell surface dynamics of the human serotonin1A receptor tagged to yellow fluorescent protein. Biochemistry (2004) 0.89
Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor. Cardiology (2003) 0.89
Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. Proc Natl Acad Sci U S A (2006) 0.89
Left ventricular pseudoaneurysm following acute myocardial infarction. Intern Med (2006) 0.89
Unconventional homologous internalization of the angiotensin II type-1 receptor induced by G-protein-independent signals. Hypertension (2005) 0.89
Manifold active-state conformations in GPCRs: agonist-activated constitutively active mutant AT1 receptor preferentially couples to Gq compared to the wild-type AT1 receptor. FEBS Lett (2007) 0.88
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res (2005) 0.88
Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis (2008) 0.88